Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin

Karadeniz C., Oguz A., Canter B., Serdaroglu A.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.17, sa.7, ss.585-590, 2000 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 7
  • Basım Tarihi: 2000
  • Doi Numarası: 10.1080/08880010050122852
  • Dergi Adı: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.585-590
  • Gazi Üniversitesi Adresli: Hayır

Özet

Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects. Most studies report incidence rates ranging from 1.5 to 3%. There is no study on the incidence rate among children with systemic malignancies. Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2 % of imipenem/cilastatin administrations was followed by a seizure attack.